AbbVie's Stock Dips 0.15% as Trading Volume Surges 108.9% to Rank 50th in Market Activity Behind Strong Q2 Earnings

On July 31, 2025, AbbVie (ABBV) closed with a 0.15% decline, trading at a volume of 1.99 billion shares—a 108.9% surge from the previous day, ranking 50th in market activity. The firm reported Q2 2025 net revenues of $15.423 billion, up 6.6% year-over-year, driven by robust performance across its Immunology and Neuroscience portfolios. Global Immunology revenue hit $7.631 billion (9.5% growth), with Skyrizi ($4.423 billion, +62.2%) and Rinvoq ($2.028 billion, +41.8%) leading gains. Neuroscience revenue rose 24.2% to $2.683 billion, buoyed by Vraylar ($900 million, +16.3%) and Botox Therapeutic ($928 million, +14.1%).

Adjusted diluted EPS for the quarter reached $2.97, a 12.1% increase, despite a $0.42 per share drag from acquired IPR&D and milestone expenses. The firm raised its 2025 adjusted EPS guidance to $11.88–$12.08, factoring in ongoing R&D costs. Strategic acquisitions, such as Capstan Therapeutics for in vivo RNA delivery technology, and regulatory milestones—including Rinvoq’s approval for giant cell arteritis and Emrelis’ accelerated approval for lung cancer—underscored its innovation pipeline. Clinical data from trials like Qulipta’s TEMPLE study and UP-AA alopecia areata trial also highlighted therapeutic advancements.

Notable headwinds emerged in the Aesthetics segment, where Botox Cosmetic revenue fell 5.0% to $692 million, and Juvederm declined 24.0%. Oncology revenue grew 2.6% to $1.676 billion, though Imbruvica dipped 9.5%. Despite these, AbbVie’s CEO emphasized “substantial momentum” entering the year’s second half, citing a diversified growth platform and regulatory progress. The stock’s muted performance contrasts with its strong operational metrics, as investors weigh long-term guidance and R&D-driven growth potential.

The strategy of purchasing the top 500 stocks by daily trading volume and holding them for one day delivered a 166.71% return from 2022 to July 30, 2025. This outperformed the benchmark return of 29.18%, generating an excess return of 137.53%. The approach’s success stems from capturing short-term momentum in high-liquidity assets, aligning with market dynamics and mitigating volatility risks through rapid turnover.